40285-9 |
Glucose^75M post dose glucose |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Glucose [Moles/volume] in Serum or Plasma --75 minutes post dose glucose |
|
MIN |
DefinitionDescription |
|
|
mmol/L |
|
|
|
|
|
|
CHAL |
|
40285-9 |
|
|
|
|
Observation |
|
|
|
0 |
Glucose 75M p Glc SerPl-sCnc |
|
|
|
N |
|
75M p Glc; After; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; GTT; Level; p dose; p Glc; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.7 |
2.15 |
|
|
|
|
|
|
|
mmol/L |
|
|
|
0 |
40286-7 |
Glucose^105M post dose glucose |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Glucose [Moles/volume] in Serum or Plasma --105 minutes post dose glucose |
|
MIN |
DefinitionDescription |
|
|
mmol/L |
|
|
|
|
|
|
CHAL |
|
40286-7 |
|
|
|
|
Observation |
|
|
|
0 |
Glucose 105M p Glc SerPl-sCnc |
|
|
|
N |
|
105M p Glc; After; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; GTT; Level; p dose; p Glc; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.7 |
2.15 |
|
|
|
|
|
|
|
mmol/L |
|
|
|
0 |
40287-5 |
Glucose^1H post meal |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Glucose [Moles/volume] in Serum or Plasma --1 hour post meal |
|
MIN |
DefinitionDescription |
|
|
mmol/L |
|
|
|
|
|
|
CHAL |
|
40287-5 |
|
|
|
|
Both |
|
|
|
0 |
Glucose 1h p meal SerPl-sCnc |
|
|
|
N |
|
1 hour; 1.0Hr; 1h p meal; 60 min; 60 minutes; 60M; 60min; After; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; GTT; Level; p meal; PC; Pl; Plasma; Plsm; Point in time; Post Pran; Post prandial; PP; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.73 |
2.15 |
|
|
|
|
|
|
|
mmol/L |
|
|
|
0 |
40288-3 |
Insulin^30M post XXX challenge |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Insulin [Moles/volume] in Serum or Plasma --30 minutes post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
pmol/L |
|
|
|
|
|
|
CHAL |
|
40288-3 |
|
|
|
|
Observation |
|
|
|
0 |
Insulin 30M p chal SerPl-sCnc |
|
|
|
N |
|
30M p chal; After; CHEMISTRY.CHALLENGE TESTING; HUM; Humulin; IH7; Insul; Lente; Level; NPH; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; Semilente; SerP; SerPl; SerPlas; Serum; Serum or plasma; Sliding; SR; Substance concentration; Ultralente |
2.7 |
2.15 |
|
|
|
|
|
|
|
pmol/L |
|
|
|
0 |
40289-1 |
Insulin^1H post XXX challenge |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Insulin [Moles/volume] in Serum or Plasma --1 hour post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
pmol/L |
|
|
|
|
|
|
CHAL |
|
40289-1 |
|
|
|
|
Observation |
|
|
|
0 |
Insulin 1h p chal SerPl-sCnc |
|
|
|
N |
|
1 hour; 1.0Hr; 1h p chal; 60 min; 60 minutes; 60M; 60min; After; CHEMISTRY.CHALLENGE TESTING; HUM; Humulin; IH7; Insul; Lente; Level; NPH; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; Semilente; SerP; SerPl; SerPlas; Serum; Serum or plasma; Sliding; SR; Substance concentration; Ultralente |
2.7 |
2.15 |
|
|
|
|
|
|
|
pmol/L |
|
|
|
0 |
4029-5 |
Secobarbital |
PrThr |
Urine |
Pt |
Ord |
|
|
ACTIVE |
Secobarbital [Presence] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
4029-5 |
|
|
|
|
Both |
|
|
|
0 |
Secobarbital Ur Ql |
|
|
|
|
|
Addiction; Barbiturate; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Illicit; Ordinal; Point in time; PotentialForAbuse; PR; QL; Qual; Qualitative; Random; Screen; Secobarb; Seconal; UA; UR; Urn |
2.73 |
1 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
40290-9 |
Insulin^1.5H post XXX challenge |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Insulin [Moles/volume] in Serum or Plasma --1.5 hours post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
pmol/L |
|
|
|
|
|
|
CHAL |
|
40290-9 |
|
|
|
|
Observation |
|
|
|
0 |
Insulin 1.5h p chal SerPl-sCnc |
|
|
|
N |
|
1 1/2 hours; 1 1/2 HR; 1.5h p chal; 1.5Hr; 90 min; 90 minutes; 90M; 90min; After; CHEMISTRY.CHALLENGE TESTING; HUM; Humulin; IH7; Insul; Lente; Level; NPH; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; Semilente; SerP; SerPl; SerPlas; Serum; Serum or plasma; Sliding; SR; Substance concentration; Ultralente |
2.7 |
2.15 |
|
|
|
|
|
|
|
pmol/L |
|
|
|
0 |
40291-7 |
Insulin^2H post XXX challenge |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Insulin [Moles/volume] in Serum or Plasma --2 hours post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
pmol/L |
|
|
|
|
|
|
CHAL |
|
40291-7 |
|
|
|
|
Observation |
|
|
|
0 |
Insulin 2h p chal SerPl-sCnc |
|
|
|
N |
|
120 min; 120 minutes; 120min; 2 hours; 2h p chal; After; CHEMISTRY.CHALLENGE TESTING; HUM; Humulin; IH7; Insul; Lente; Level; NPH; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; Semilente; SerP; SerPl; SerPlas; Serum; Serum or plasma; Sliding; SR; Substance concentration; Ultralente |
2.7 |
2.15 |
|
|
|
|
|
|
|
pmol/L |
|
|
|
0 |
40292-5 |
Insulin^2.5H post XXX challenge |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Insulin [Moles/volume] in Serum or Plasma --2.5 hours post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
pmol/L |
|
|
|
|
|
|
CHAL |
|
40292-5 |
|
|
|
|
Observation |
|
|
|
0 |
Insulin 2.5h p chal SerPl-sCnc |
|
|
|
N |
|
2.5h p chal; After; CHEMISTRY.CHALLENGE TESTING; HUM; Humulin; IH7; Insul; Lente; Level; NPH; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; Semilente; SerP; SerPl; SerPlas; Serum; Serum or plasma; Sliding; SR; Substance concentration; Ultralente |
2.7 |
2.15 |
|
|
|
|
|
|
|
pmol/L |
|
|
|
0 |
40293-3 |
Insulin^3H post XXX challenge |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Insulin [Moles/volume] in Serum or Plasma --3 hours post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
pmol/L |
|
|
|
|
|
|
CHAL |
|
40293-3 |
|
|
|
|
Observation |
|
|
|
0 |
Insulin 3h p chal SerPl-sCnc |
|
|
|
N |
|
3h p chal; After; CHEMISTRY.CHALLENGE TESTING; HUM; Humulin; IH7; Insul; Lente; Level; NPH; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; Semilente; SerP; SerPl; SerPlas; Serum; Serum or plasma; Sliding; SR; Substance concentration; Ultralente |
2.7 |
2.15 |
|
|
|
|
|
|
|
pmol/L |
|
|
|
0 |
40294-1 |
Insulin^pre or post dose glucose |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Insulin [Moles/volume] in Serum or Plasma --pre or post dose glucose |
|
MIN |
DefinitionDescription |
|
|
pmol/L |
|
|
|
|
|
|
CHAL |
|
40294-1 |
|
|
|
|
Observation |
|
|
|
0 |
Insulin pre/p Glc SerPl-sCnc |
|
|
|
N |
|
After; Before; CHEMISTRY.CHALLENGE TESTING; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; GTT; HUM; Humulin; IH7; Insul; Lente; Level; NPH; p dose; p Glc; Pl; Plasma; Plsm; Point in time; pre/p Glc; PST; QNT; Quan; Quant; Quantitative; Random; Semilente; SerP; SerPl; SerPlas; Serum; Serum or plasma; Sliding; SR; Substance concentration; Ultralente |
2.7 |
2.15 |
|
|
|
|
|
|
|
pmol/L |
|
|
|
0 |
40295-8 |
Triiodothyronine.free^2H post XXX challenge |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Triiodothyronine (T3) Free [Moles/volume] in Serum or Plasma --2 hours post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
pmol/L;nmol/L |
|
|
|
|
|
|
CHAL |
|
40295-8 |
|
|
|
|
Observation |
|
|
|
0 |
T3Free 2h p chal SerPl-sCnc |
|
|
|
N |
|
120 min; 120 minutes; 120min; 2 hours; 2h p chal; After; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; FR; Free T3; FT3; Level; Non-protein bound; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration; T3; T-3; T3Free; thyroid hormone; Total T3; Triodothyrne |
2.7 |
2.15 |
|
|
|
|
|
|
|
pmol/L |
|
|
|
0 |
40296-6 |
Xylose^post CFst |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Xylose [Moles/volume] in Serum or Plasma --fasting |
|
MIN |
DefinitionDescription |
|
|
mmol/L;nmol/L |
|
|
|
|
|
|
CHAL |
|
40296-6 |
|
|
|
|
Observation |
|
|
|
0 |
Xylose p fast SerPl-sCnc |
|
|
|
N |
|
After; Calorie Fast; CHEMISTRY.CHALLENGE TESTING; D-xylose; Fast; Fasting; Level; p fast; PC; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration; Xylose absorption test |
2.7 |
2.15 |
|
|
|
|
|
|
|
mmol/L |
|
|
|
0 |
40297-4 |
Somatotropin^3.5H post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Somatotropin [Mass/volume] in Serum or Plasma --3.5 hours post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ug/L;ng/mL |
|
|
|
|
|
|
CHAL |
|
40297-4 |
|
|
|
|
Observation |
|
|
|
0 |
GH 3.5h p chal SerPl-mCnc |
|
|
|
N |
|
3.5h p chal; After; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; GH; Growth hormone; HGH; Human growth hormone; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Somatotropic hormone; SR; STH |
2.73 |
2.15 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
40298-2 |
Somatotropin^pre dose cloNIDine |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Somatotropin [Mass/volume] in Serum or Plasma --pre dose cloNIDine |
|
MIN |
DefinitionDescription |
|
|
ug/L;ng/mL |
|
|
|
|
|
|
CHAL |
|
40298-2 |
|
|
|
|
Observation |
|
|
|
0 |
GH pre CLN SerPl-mCnc |
|
|
|
N |
|
Before; Catapres; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; GH; Growth hormone; HGH; Human growth hormone; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; pre CLN; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Somatotropic hormone; SR; STH |
2.7 |
2.15 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
40299-0 |
Somatotropin^1H post dose cloNIDine |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Somatotropin [Mass/volume] in Serum or Plasma --1 hour post dose cloNIDine |
|
MIN |
DefinitionDescription |
|
|
ug/L;ng/mL |
|
|
|
|
|
|
CHAL |
|
40299-0 |
|
|
|
|
Observation |
|
|
|
0 |
GH 1h p CLN SerPl-mCnc |
|
|
|
N |
|
1 hour; 1.0Hr; 1h p CLN; 60 min; 60 minutes; 60M; 60min; After; Catapres; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; GH; Growth hormone; HGH; Human growth hormone; Level; Mass concentration; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Somatotropic hormone; SR; STH |
2.73 |
2.15 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
403-6 |
Pipemidate |
Susc |
Isolate |
Pt |
Qn |
MLC |
|
ACTIVE |
Pipemidate [Susceptibility] by Minimum lethal concentration (MLC) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
403-6 |
|
MLC |
|
|
Observation |
|
|
|
0 |
Pipemidate Islt MLC |
|
|
|
Y |
|
Acipern; ANTIBIOTIC SUSCEPTIBILITIES; AST; Biopim; Cistomid; Deblaston; Diperpen; Dokol; Faremid; Filtrax; Galusan; ID; Impresial; Infectious Disease; InfectiousDisease; Islt; Isol; MBC; Minimum bactericidal concentration; Minimum lethal concentration; Nuril; Pipeacid; Pipedac; Pipedose; Pipefort; Pipemid; Pipemidic acid; Piperamic acid; Pipram; Pipurin; Point in time; Pro-uro; QNT; Quan; Quant; Quantitative; Random; Septidron; Solupemid; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; Tractur; Urisan; Urodene |
2.19 |
1 |
|
|
|
|
|
|
|
|
|
|
|
0 |
4030-3 |
Sotalol |
PrThr |
Urine |
Pt |
Ord |
|
|
ACTIVE |
Sotalol [Presence] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
4030-3 |
|
|
|
|
Both |
|
|
|
0 |
Sotalol Ur Ql |
|
|
|
|
|
Beta-cardone; Betapace; Betudes; DRUG/TOXICOLOGY; Drugs; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Solalex; Sotacor; UA; UR; Urn |
2.56 |
1 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
40300-6 |
Somatotropin^1.5H post dose cloNIDine |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Somatotropin [Mass/volume] in Serum or Plasma --1.5 hours post dose cloNIDine |
|
MIN |
DefinitionDescription |
|
|
ug/L;ng/mL |
|
|
|
|
|
|
CHAL |
|
40300-6 |
|
|
|
|
Observation |
|
|
|
0 |
GH 1.5h p CLN SerPl-mCnc |
|
|
|
N |
|
1 1/2 hours; 1 1/2 HR; 1.5h p CLN; 1.5Hr; 90 min; 90 minutes; 90M; 90min; After; Catapres; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; GH; Growth hormone; HGH; Human growth hormone; Level; Mass concentration; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Somatotropic hormone; SR; STH |
2.73 |
2.15 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
40301-4 |
Somatotropin^2H post dose cloNIDine |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Somatotropin [Mass/volume] in Serum or Plasma --2 hours post dose cloNIDine |
|
MIN |
DefinitionDescription |
|
|
ug/L;ng/mL |
|
|
|
|
|
|
CHAL |
|
40301-4 |
|
|
|
|
Observation |
|
|
|
0 |
GH 2h p CLN SerPl-mCnc |
|
|
|
N |
|
120 min; 120 minutes; 120min; 2 hours; 2h p CLN; After; Catapres; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; GH; Growth hormone; HGH; Human growth hormone; Level; Mass concentration; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Somatotropic hormone; SR; STH |
2.73 |
2.15 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
40302-2 |
Somatotropin^pre dose arginine |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Somatotropin [Mass/volume] in Serum or Plasma --pre dose arginine |
|
MIN |
DefinitionDescription |
|
|
ug/L;ng/mL |
|
|
|
|
|
|
CHAL |
|
40302-2 |
|
|
|
|
Observation |
|
|
|
0 |
GH pre Arg SerPl-mCnc |
|
|
|
N |
|
Arg; Before; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; GH; Growth hormone; HGH; Human growth hormone; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; pre Arg; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Somatotropic hormone; SR; STH |
2.7 |
2.15 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
40303-0 |
Somatotropin^1H post dose arginine |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Somatotropin [Mass/volume] in Serum or Plasma --1 hour post dose arginine |
|
MIN |
DefinitionDescription |
|
|
ug/L;ng/mL |
|
|
|
|
|
|
CHAL |
|
40303-0 |
|
|
|
|
Observation |
|
|
|
0 |
GH 1h p Arg SerPl-mCnc |
|
|
|
N |
|
1 hour; 1.0Hr; 1h p Arg; 60 min; 60 minutes; 60M; 60min; After; Arg; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; GH; Growth hormone; HGH; Human growth hormone; Level; Mass concentration; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Somatotropic hormone; SR; STH |
2.73 |
2.15 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
40304-8 |
Somatotropin^1.5H post dose arginine |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Somatotropin [Mass/volume] in Serum or Plasma --1.5 hours post dose arginine |
|
MIN |
DefinitionDescription |
|
|
ug/L;ng/mL |
|
|
|
|
|
|
CHAL |
|
40304-8 |
|
|
|
|
Both |
|
|
|
0 |
GH 1.5h p Arg SerPl-mCnc |
|
|
|
N |
|
1 1/2 hours; 1 1/2 HR; 1.5h p Arg; 1.5Hr; 90 min; 90 minutes; 90M; 90min; After; Arg; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; GH; Growth hormone; HGH; Human growth hormone; Level; Mass concentration; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Somatotropic hormone; SR; STH |
2.73 |
2.15 |
|
|
|
|
|
|
|
ng/mL |
|
|
Changed Order_Obs from 'Observation Only' to 'Both' to fit current order use cases. |
0 |
40305-5 |
Somatotropin^2H post dose arginine |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Somatotropin [Mass/volume] in Serum or Plasma --2 hours post dose arginine |
|
MIN |
DefinitionDescription |
|
|
ug/L;ng/mL |
|
|
|
|
|
|
CHAL |
|
40305-5 |
|
|
|
|
Both |
|
|
|
0 |
GH 2h p Arg SerPl-mCnc |
|
|
|
N |
|
120 min; 120 minutes; 120min; 2 hours; 2h p Arg; After; Arg; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; GH; Growth hormone; HGH; Human growth hormone; Level; Mass concentration; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Somatotropic hormone; SR; STH |
2.73 |
2.15 |
|
|
|
|
|
|
|
ng/mL |
|
|
Changed Order_Obs from 'Observation Only' to 'Both' to fit current order use cases. |
0 |
40306-3 |
Somatotropin^3H post dose arginine |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Somatotropin [Mass/volume] in Serum or Plasma --3 hours post dose arginine |
|
MIN |
DefinitionDescription |
|
|
ug/L;ng/mL |
|
|
|
|
|
|
CHAL |
|
40306-3 |
|
|
|
|
Observation |
|
|
|
0 |
GH 3h p Arg SerPl-mCnc |
|
|
|
N |
|
3h p Arg; After; Arg; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; GH; Growth hormone; HGH; Human growth hormone; Level; Mass concentration; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Somatotropic hormone; SR; STH |
2.7 |
2.15 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |